Infezioni resistenti agli antibiotici

Antibiotic-resistant infections are bacterial illnesses that no longer respond to standard antibiotics because the microbes have evolved mechanisms to survive drug exposure. This is a concern because it leads to longer hospital stays, higher medical costs, and increased mortality. For example, the CDC reports over 2.8 million resistant infections and roughly 35,000 deaths annually in the United States. Dr. Tommaso Richelmi notes that resistance threatens routine procedures like surgery and chemotherapy, making infections harder to control.

Oxygen-ozone therapy can help treat resistant infections by generating reactive oxygen species that damage bacterial cell walls, membranes, and DNA, thereby killing microbes that evade antibiotics. Laboratory studies show ozone at 20 µg/ml achieves a 99 % reduction of MRSA biofilms within 30 minutes. Dr. Tommaso Richelmi explains that the therapy also modulates the host immune response, enhancing phagocytosis and reducing inflammation, which supports clearance of resistant strains when used alongside conventional care.

Signs of an antibiotic-resistant infection include persistent fever above 38 °C lasting more than 48 hours despite appropriate antibiotic therapy, worsening pain or swelling at the infection site, and laboratory markers such as a white‑blood‑cell count exceeding 12,000 /µL or elevated C‑reactive protein >10 mg/L. Dr. Tommaso Richelmi adds that non‑healing wounds or recurrent abscesses after a full course of drugs are strong clinical clues that resistance may be present.

Alternative treatments for antibiotic-resistant infections include bacteriophage therapy, which uses viruses that specifically target and lyse bacteria; clinical compassionate‑use cases report ~70 % success against multidrug‑resistant Pseudomonas aeruginosa. Other options are antimicrobial peptides, monoclonal antibodies, and adjuvant therapies like oxygen‑ozone treatment that disrupt bacterial defenses. Dr. Tommaso Richelmi stresses that these alternatives are most effective when tailored to the pathogen’s susceptibility profile and used under specialist supervision.

Preventing antibiotic resistance relies on reducing unnecessary antibiotic exposure and limiting transmission of resistant strains. Key measures are strict hand‑hygiene compliance, which can cut cross‑infection rates by up to 40 %, and antimicrobial stewardship programs that decrease inappropriate prescriptions by roughly 30 %. Dr. Tommaso Richelmi also recommends vaccinations against common bacterial pathogens and proper isolation of infected patients in healthcare settings to curb spread.

Probiotics help manage infections by restoring a balanced microbiota, competing with pathogenic bacteria, and modulating immune defenses. Specific strains such as Lactobacillus rhamnosus GG have been shown in a meta‑analysis of 20 randomized trials to lower the risk of Clostridioides difficile recurrence by about 50 %. Dr. Tommaso Richelmi cautions that probiotic benefits are strain‑specific and should be used as an adjunct, not a replacement, for targeted antimicrobial therapy when resistance is suspected.